Deprescribing in Patients Living With Dementia With Caregiver and Provider Nudges (NCT06347172) | Clinical Trial Compass
CompletedNot Applicable
Deprescribing in Patients Living With Dementia With Caregiver and Provider Nudges
United States262 participantsStarted 2024-08-01
Plain-language summary
The objectives of this study are to demonstrate the feasibility of implementing a deprescribing nudge intervention using pragmatic methods, confirm that outcomes can be feasibly measured and evaluated at scale in a subsequent embedded pragmatic clinical trial (ePCT), and explore representativeness of persons living with dementia and care partners identified.
Who can participate
Age range
65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Primary care providers will be the primary unit of identification and randomization.
Primary care providers inclusion criteria:
* Providers within Brigham and Women's Hospital primary care practices
* Having prescribed at least one of the high-risk medications of interest
Eligible patients will be identified through this providers within the health care system.
Patient inclusion criteria:
* At least 65 years of age
* Prescribed at least 90 pills of one of the high-risk medications of interest in the last 180 days in the EHR system, which most guidelines consider chronic use, and have a diagnosis of dementia in the EHR.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial focused on 'deprescribing' for people living with dementia — can you explain what that means in practice, and whether any of my current medications might be worth reconsidering given my diagnosis?
2The study tested whether sending information nudges to both caregivers and doctors before a primary care visit actually changed how medications were reviewed — now that the trial is completed, has anything from this kind of approach been shared or applied in your practice?
3Since this was a study about how information gets communicated before appointments rather than testing a specific drug or treatment, what does that mean for how I should think about bringing up medication concerns at my own visits going forward?
4The trial involved people with Alzheimer's disease and mild cognitive impairment — given where I am in my diagnosis, is deprescribing something my care team thinks I should be actively discussing right now, or is it more relevant at a later stage?
5Are there specific types of medications — for example, ones with known risks for people with dementia — that this kind of deprescribing research typically targets, and should we be looking at my current medication list with that in mind?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Composite of the Percentage of Eligible PCPs or Their PLWD/Care Partners Who View or Click on Information on or Before the Primary Care Provider Visit, up to 10 Days
Timeframe: On or before the primary care provider visit, up to 10 days